Kingscrowd’s Post

🔬 The transition towards biomanufacturing, and the move away from traditional, energy-intensive processes in industry is creating unprecedented opportunities for start-ups. Understanding the investor's perspective in this space can help founders prepare more effectively for their fundraise. Investment Manager, Dr Marina Fuentes, details the most critical aspects Mercia Ventures and other investors look for at the Series A stage. Read more ⏬ #BioManufacturing #Blog #Investor #VentureCapital #Investment #SeriesA #Founders #Opportunity #Learning

Financing innovation or tactics in the shadows - Where do you stand?   It’s certainly no secret, every week we’re seeing a press release… Across biotech, billions of dollars have already been raised YTD, through more than 25 transactions of this kind – the PIPE.   In days of old, it had the reputation for being a “last resort” instead of a traditional follow on, but not anymore. We’ve seen them rise in prevalence, become more mainstream and PIPE transactions have now cemented themselves as the latest trendy way to raise capital - well they certainly have for the beginning of '24.   With questions now being asked by many in regard to it's transparency - do you think the modern PIPE is really a fair and ethical way to raise money?   The total global biotech sector value rose 10.3% last week and the biotech market has now been up 15 of the last 17 weeks.

🔬 The transition towards biomanufacturing, and the move away from traditional, energy-intensive processes in industry is creating unprecedented opportunities for start-ups. Understanding the investor's perspective in this space can help founders prepare more effectively for their fundraise. Investment Manager, Dr Marina Fuentes, details the most critical aspects Mercia Ventures and other investors look for at the Series A stage. Read more ⏬ #BioManufacturing #Blog #Investor #VentureCapital #Investment #SeriesA #Founders #Opportunity #Learning

🔬 The transition towards biomanufacturing, and the move away from traditional, energy-intensive processes in industry is creating unprecedented opportunities for start-ups. Understanding the investor's perspective in this space can help founders prepare more effectively for their fundraise. Investment Manager, Dr Marina Fuentes, details the most critical aspects Mercia Ventures and other investors look for at the Series A stage. Read more ⏬ #BioManufacturing #Blog #Investor #VentureCapital #Investment #SeriesA #Founders #Opportunity #Learning

🔬 The transition towards biomanufacturing, and the move away from traditional, energy-intensive processes in industry is creating unprecedented opportunities for start-ups. Understanding the investor's perspective in this space can help founders prepare more effectively for their fundraise. Investment Manager, Dr Marina Fuentes, details the most critical aspects Mercia Ventures and other investors look for at the Series A stage. Read more ⏬ #BioManufacturing #Blog #Investor #VentureCapital #Investment #SeriesA #Founders #Opportunity #Learning

🔬 The transition towards biomanufacturing, and the move away from traditional, energy-intensive processes in industry is creating unprecedented opportunities for start-ups. Understanding the investor’s perspective in this space can help founders prepare more effectively for their fundraise. Investment Manager, Dr Marina Fuentes, details the most critical aspects Mercia Ventures and other investors look for at the Series A stage including: 💷 High-Value vs High Volume 🤝 Business model 📈 Traction 🚀 Commercial dynamics More ⏬ #BioManufacturing #Blog #Investor #VentureCapital #Investment #SeriesA #Founders #Opportunity #Learning

An interesting read - Give this a look at!

Really enjoyed my conversation with David Kereiakes on the state of #medtech and #healthtech funding. David offers fascinating insights into the current state of affairs and the opportunities that lie ahead. David recently took on the role of Managing Partner in Windham Venture Partners' Cincinnati office, where he'll leverage more than ten years of experience investing in healthcare innovation to help Windham continue to scale and tap into the innovation happening in Ohio and other Midwestern states. Check out the whole interview below! #venturecapital #medtech #healthtech #healthcareinnovation

Dive into the latest insights on the state of MedTech funding in 2023 as David Kereiakes, Partner at Windham Venture Partners, sits down with Francisco Javier Perez, CFA to uncover the shifting landscape and opportunities in MedTech investments. Read the full interview to learn more: https://bit.ly/3POqKTe. #investment #medtech #healthtech #funding

I broke down what you need to know about biopharma startups from Jonathan Norris's mid-year report for HSBC Innovation Banking. The takeaways: - Seed + Series A-stage investment in 2023 is on pace to be down 40% from 2022 - Clinical data is key for any company trying to raise capital - ARCH Venture Partners was most active in the first half of 2023, followed by RA Capital Management and Sofinnova Partners. What does this all mean for the #biotech industry? My latest insights for BioPharma Dive: https://lnkd.in/gCP8XPuS